Clinical comparison of the anticalculus efficacy of three commercially available dentifrices.
A three-month, double-blind, parallel and unsupervised clinical study was conducted to compare the effects on supragingival calculus formation of the following four dentifrices: 1) A placebo dentifrice containing 0.243% sodium fluoride in a silica base. 2) A commercially available anticalculus dentifrice containing 5.0% soluble pyrophosphate in a 0.243% sodium fluoride silica base. 3) A commercially available anticalculus dentifrice containing 1.3% soluble pyrophosphate and 1.5% of a Gantrez copolymer in a 0.243% sodium fluoride silica base. 4) A commercially available anticalculus dentifrice containing 3.3% soluble pyrophosphate and 1.0% of a Gantrez copolymer in a 0.243% sodium fluoride silica base. The three-month results indicated that the three commercially available anticalculus dentifrices provided statistically significant reductions (at the 99% level of confidence) in supragingival calculus formation of 43.87%, 46.60%, and 51.32% respectively, as compared to the placebo dentifrice. There was no statistically significant difference among the three commercially available anticalculus dentifrices.